Based on preliminary financial information, the Company expects Q3 total revenue, which includes license and royalty revenue from partners, to be in the range of $42M-$44M and U.S. XPOVIO net product revenue to be approximately $32M. Prior to the receipt of approximately $36 million of gross proceeds from the financing transactions, the Company expects to report that it had cash, cash equivalents, restricted cash and investments as of September 30 of approximately $46M. The financial information presented in this press release reflects the Company’s estimates with respect to total revenue, U.S. XPOVIO net product revenue and its cash balance and is based on currently available information, which is preliminary.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Selinexor Study Withdrawal: Implications for Karyopharm Therapeutics
- Karyopharm Therapeutics Board Member Resigns Amid Career Shift
- Karyopharm completes enrollment in Phase 3 Sentry trial
- Cautious Hold on Karyopharm Therapeutics Amid Revenue Guidance Cut and Clinical Delays
- Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain